Literature DB >> 16306998

Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients.

R Fogari1, A Mugellini, A Zoppi, P Lazzari, M Destro, A Rinaldi, P Preti.   

Abstract

The aim of this study was to compare the effects of telmisartan/hydrochlorothiazide (HCTZ) vs lisinopril/HCTZ combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. A total of 160 patients, 76 men and 84 women, aged 61-75 years, with sitting diastolic blood pressure (DBP)>90 mmHg and <110 mmHg and systolic blood pressure (SBP)>140 mmHg were randomized to receive temisartan 80 mg/HCTZ 12.5 mg o.d. or lisinopril 20 mg/HCTZ 12.5 mg o.d. for 24 weeks, according to a prospective, open-label, blinded end point, parallel-group design. At the end of a 2-week wash-out period and after 12 and 24 weeks of active treatment, 24-h noninvasive ambulatory BP monitoring (ABPM) was performed and cognitive function was evaluated through six different tests (verbal fluency, Boston naming test, word-list memory, word-list recall, word-list recognition and Trails B). Both treatments significantly reduced ambulatory BP. However, the telmisartan/HCTZ combination produced a greater reduction in 24-h, day-time and night time ABPM values. Lisinopril/HCTZ did not induce significant changes in any of the cognitive function test scores at any time of the study, whereas at both 12 and 24 weeks telmisartan/HCTZ significantly improved the word-list memory score (+17.1 and +15.7%, respectively, P<0.05 vs baseline), the word-list recall score (+13.5 and +16.9%, P<0.05) and the Trails B score (-33 and -30.5%, P<0.05). These results suggest that in elderly hypertensive patients treatment with telmisartan/HCTZ produces a slightly greater reduction in ambulatory BP than lisinopril/HCTZ combination and, unlike this latter, improves some of the components of cognitive function, particularly episodic memory and visuospatial abilities.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16306998     DOI: 10.1038/sj.jhh.1001964

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  26 in total

Review 1.  Updated report on comparative effectiveness of ACE inhibitors, ARBs, and direct renin inhibitors for patients with essential hypertension: much more data, little new information.

Authors:  Benjamin J Powers; Remy R Coeytaux; Rowena J Dolor; Vic Hasselblad; Uptal D Patel; William S Yancy; Rebecca N Gray; R Julian Irvine; Amy S Kendrick; Gillian D Sanders
Journal:  J Gen Intern Med       Date:  2011-12-07       Impact factor: 5.128

2.  Gerontology forum: an update on the literature.

Authors: 
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 3.  The relationship between blood pressure and cognitive function.

Authors:  Vera Novak; Ihab Hajjar
Journal:  Nat Rev Cardiol       Date:  2010-10-26       Impact factor: 32.419

Review 4.  Antihypertensive Therapies and Cognitive Function: a Review.

Authors:  Nisharahmed Kherada; Todd Heimowitz; Clive Rosendorff
Journal:  Curr Hypertens Rep       Date:  2015-10       Impact factor: 5.369

5.  Cognitive enhancement following acute losartan in normotensive young adults.

Authors:  Rasha Mechaeil; Paul Gard; Anne Jackson; Jennifer Rusted
Journal:  Psychopharmacology (Berl)       Date:  2011-04-12       Impact factor: 4.530

6.  Cognition and Hemodynamics.

Authors:  Vera Novak
Journal:  Curr Cardiovasc Risk Rep       Date:  2012-10

Review 7.  Clinical Trials of Blood Pressure Lowering and Antihypertensive Medication: Is Cognitive Measurement State-of-the-Art?

Authors:  Merrill F Elias; Rachael V Torres; Adam Davey
Journal:  Am J Hypertens       Date:  2018-05-07       Impact factor: 2.689

Review 8.  Olmesartan vs. ramipril in elderly hypertensive patients: review of data from two published randomized, double-blind studies.

Authors:  Stefano Omboni; Ettore Malacco; Jean-Michel Mallion; Paolo Fabrizzi; Massimo Volpe
Journal:  High Blood Press Cardiovasc Prev       Date:  2014-01-17

Review 9.  New standards in hypertension and cardiovascular risk management: focus on telmisartan.

Authors:  Domenico Galzerano; Cristina Capogrosso; Sara Di Michele; Antonio Galzerano; Paola Paparello; Diana Lama; Carlo Gaudio
Journal:  Vasc Health Risk Manag       Date:  2010-03-24

Review 10.  Cognitive-enhancing effects of angiotensin IV.

Authors:  Paul R Gard
Journal:  BMC Neurosci       Date:  2008-12-03       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.